TWO CASES OF ANTIPSYCHOTIC USE IN CHILD PSYCHIATRY

Abstract

The article deals with the safety of antipsychotics, especially for children and adolescents. Two examples of the unreasonable and unsafe use of antipsychotics in children’s psychiatric clinics are given. It is emphasized that the use of antipsychotics at a young age increases the risk of heart and metabolic diseases and contributes to increased mortality.

References

[1] Авруцкий Г.Я., Недува А.А. Лечение психически больных: руководство для врачей. 2-е издание, дополненное и переработанное. М.: Медицина. 1988. 527 с.

[2] Менделевич В.Д. Классификация психических расстройств vs систематика поведенческих девиаций: медикализация как тренд // Обозрение психиатрии и медицинской психологии. 2016. №1. С. 10-16.

[3] Coghill D., Bonnar S., Duke S.L. et al. Child and Adolescent Psychiatry. Oxford: Oxford University Press, 2009. 491 p.

[4] Eapen V., Shiers D., Curtis J. Bridging the gap from evidence to policy and practice: reducing the progression to metabolic syndrome for children and adolescents on antipsychotic medication // Aust-N-Z-J-Psychiatry. 2013. Vol. 47 (5). P. 435-442.

[5] Ginovart N., Kapur S. Role of dopamine D (2) receptors for antipsychotic activity // Handb-Exp-Pharmacol. 2012. Vol. 212. P. 27-52.

[6] Harrison P., Cowen P., Burns T., Fazel M. Shorter Oxford Textbook of Psychiatry. Seventh Edition. Oxford: Oxford University Press, 2018. 1681 p.

[7] Kapur S., Remington G., Jones C. et al. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study // Am-J-Psychiatry. 1996. Vol. 153 (7). P. 948-950.

[8] Kumar A., Datta S.S., Wright S.D. et al. Atypical antipsychotics for psychosis in adolescents // Cochrane-Database-Syst-Rev. 2013. Vol. 10. CD009582.

[9] Lytle S., McVoy M., Sajatovic M. Long-acting injectable antipsychotics in children and adolescents // J-Child-Adolesc-Psychopharmacol. 2017. Vol. 27 (1). P. 2-9.

[10] Matera E., Margari L., Palmieri V.O. et al. Risperidone and cardiometabolic risk in children and adolescents: clinical and instrumental issues // J-Clin-Psychopharmacol. 2017. Vol. 37 (3). P. 302-309.

[11] Pagsberg A.K., Tarp S., Glintborg D. et al. Acute antipsychotic treatment of children and adolescents with schizophrenia-spectrum disorders: a systematic review and network meta-analysis // J-Am-Acad-Child-Adolesc-Psychiatry. 2017. Vol. 56 (3). P. 191-202.

[12] Pramyothin P., Khaodhiar L. Type 2 diabetes in children and adolescents on atypical antipsychotics // Curr-Diab-Rep. 2015. Vol. 15 (8). P. 53.

[13] Rani F.A., Byrne P., Cranswick N. et al. Mortality in children and adolescents prescribed antipsychotic medication: a retrospective cohort study using the UK general practice research database // Drug-Saf. 2011. Vol. 34 (9). P. 773-781.

[14] Ray W.A., Stein C.M., Murray K.T. et al. Association of antipsychotic treatment with risk of unexpected death among children and youths // JAMA-Psychiatry. 2018. doi: 10.1001/jamapsychiatry.2018.3421. [Epub ahead of print]

[15] Reekie J., Hosking S.P., Prakash C. et al. The effect of antidepressants and antipsychotics on weight gain in children and adolescents // Obes-Rev. 2015. Vol. 16 (7). P. 566-580.

[16] Shin L., Bregman H., Frazier J., Noyes N. An overview of obesity in children with psychiatric disorders taking atypical antipsychotics // Harv-Rev-Psychiatry. 2008. Vol. 16 (2). P. 69-79.

[17] Yang C., Hao Z., Tian J. et al. Does antipsychotic drug use increase the risk of long term mortality? A systematic review and meta-analysis of observational studies // Oncotarget. 2018. Vol. 9 (19). P. 15101-15110.

RIGHTS & PERMISSIONS

Portnova A.A., Sivolap Y.P.